Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Linaclotide (Linzess) vs Rezafungin (Rezzayo)
An educational, source-based comparison of Linaclotide (Linzess) and Rezafungin (Rezzayo) — how each peptide works, what it's researched for, and what to know before going deeper.
Guanylate cyclase-C agonist peptide for IBS-C and chronic constipation.
14-amino-acid peptide that activates intestinal guanylate cyclase-C, increasing cGMP and chloride/bicarbonate secretion into the gut lumen — accelerating transit and reducing visceral pain.
- IBS-C
- Chronic idiopathic constipation
- Functional constipation in children
- • FDA-approved.
- • Contraindicated in children <2 years; diarrhea common.
Once-weekly echinocandin for candidemia and invasive candidiasis.
Next-generation echinocandin structurally related to anidulafungin with enhanced stability, inhibiting β-(1,3)-D-glucan synthase; long half-life permits once-weekly IV dosing.
- Candidemia
- Invasive candidiasis
- • FDA-approved (2023).
- • Infusion reactions and photosensitivity reported.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Linaclotide (Linzess) | Linaclotide phase 3 trials | NEJM | 2011 | Improved abdominal pain and bowel function in IBS-C. |
| Rezafungin (Rezzayo) | ReSTORE trial | Lancet | 2023 | Non-inferior to caspofungin for candidemia/invasive candidiasis. |
Side-effect & safety grid
- FDA-approved.
- Contraindicated in children <2 years; diarrhea common.
- FDA-approved (2023).
- Infusion reactions and photosensitivity reported.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Linaclotide (Linzess) vs Rezafungin (Rezzayo) — Key differences
- Class: Linaclotide (Linzess) is classified as GC-C Agonist · Gastrointestinal, while Rezafungin (Rezzayo) is Echinocandin · Antifungal.
- Primary research focus: Linaclotide (Linzess) — ibs-c; Rezafungin (Rezzayo) — candidemia.
- Tag: FDA-Approved · GI vs FDA-Approved · Antifungal.